🚽 Recurrent UTI Prophylaxis Simulator

Recurrent Cystitis Without Prophylaxis

Untreated recurrence repeats several times a year in susceptible patients.

• ≥2/6mo: Definition (or ≥3 episodes per year)
• 2–12/yr: Typical baseline (episodes without prevention)
• Premenopausal: Peak risk group (sexually active women)
• Postmenopausal: Second peak (estrogen-deficiency related)

Why baseline pattern matters for strategy choice

Placeholder: recurrence frequency and trigger pattern guide which prophylaxis strategy fits best.

Placeholder: baseline episode count anchors every comparison in later stages.

Single-Dose Antibiotic After Intercourse

A single antibiotic dose taken after sex targets coitus-triggered infections.

• ~85%: Relative reduction (in coitus-linked recurrence)
• 1 dose: Dosing (within hours of intercourse)
• Coital pattern: Best candidate (clear temporal trigger)
• Lower: Antibiotic exposure (vs. daily continuous dosing)

When post-coital dosing is preferred

Placeholder: post-coital dosing suits patients whose episodes cluster after intercourse.

Placeholder: lower cumulative antibiotic exposure is a key advantage.

Daily Low-Dose Antibiotic Suppression

Daily low-dose antibiotics suppress recurrence regardless of trigger timing.

• ~90%: Relative reduction (across trial durations)
• 3–12 mo: Typical duration (continuous course)
• Non-coital, frequent: Best candidate (unpredictable pattern)
• Resistance risk: Main tradeoff (long-term antibiotic exposure)

Tradeoffs of continuous suppression

Placeholder: continuous prophylaxis trades higher antibiotic exposure for stronger suppression.

Placeholder: adherence and resistance concerns limit long-term continuous use.

Vaginal Estrogen for Postmenopausal Recurrence

Local estrogen therapy targets postmenopausal urogenital tissue changes.

• ~55%: Relative reduction (in postmenopausal recurrence)
• Tissue atrophy: Mechanism target (not antibiotic-based)
• Postmenopausal: Best candidate (estrogen-deficient women)
• None: Antibiotic exposure (non-antibiotic strategy)

Non-antibiotic option for menopausal patients

Placeholder: vaginal estrogen addresses menopause-related recurrence without antibiotics.

Placeholder: well tolerated for long-term local use in menopause.

Choosing Among Prophylaxis Strategies

Strategy choice depends on trigger pattern, menopausal status, and tolerance.

• Coital pattern: Post-coital fit (lowest antibiotic exposure)
• Frequent, non-coital: Continuous fit (strongest suppression)
• Menopausal: Estrogen fit (non-antibiotic option)
• Fewer episodes: Shared goal (balanced against burden)

Matching strategy to patient profile

Placeholder: comparing curves side by side highlights the best-fit strategy per patient.

Placeholder: no single strategy is universally superior across all patients.